Resveratrol: Development discontinued

GlaxoSmithKline discontinued development of SRT501 after data from an open-label Phase IIa trial in 24 patients showed that SRT501 displayed only minimal efficacy with the potential to indirectly exacerbate renal complications in MM patients. In April, GSK suspended enrollment in the trial after observing an increase in the incidence of cast nephropathy, a condition that can cause renal failure (see BioCentury, May 10). The pharma also said that the 5 cases of acute renal failure observed in the trial were most likely due to underlying disease. However, SRT501 was not well tolerated, and side effects of nausea, vomiting and diarrhea may have indirectly led to dehydration, which exacerbated the development of acute renal failure. ...